Astellas Pharma: Difference between revisions
No edit summary |
|||
| Line 22: | Line 22: | ||
'''Fujisawa Shoten''' was started in 1894 by [[Tomokichi Fujisawa]] in [[Osaka]], and was renamed '''Fujisawa Pharmaceutical Co.''' in 1943. |
'''Fujisawa Shoten''' was started in 1894 by [[Tomokichi Fujisawa]] in [[Osaka]], and was renamed '''Fujisawa Pharmaceutical Co.''' in 1943. |
||
'''Yamanouchi Yakuhin Shokai''' was started in 1923 by [[Kenji Yamanouchi]] in Osaka. The company was renamed '''Yamanouchi Pharmaceutical Co.''' in 1940 and |
'''Yamanouchi Yakuhin Shokai''' was started in 1923 by [[Kenji Yamanouchi]] in Osaka. The company was renamed '''Yamanouchi Pharmaceutical Co.''' in 1940 and moved to [[Tokyo]] in 1942. |
||
Both companies started their overseas expansion at about the same time, opening offices in [[Taiwan]] in 1962 and 1963, respectively, and in the [[United States]] and Europe from 1977 onwards. Fujisawa acquired '''Lyphomed''' in 1990 and thereafter established its US R&D centre in [[Deerfield, Illinois]]. Yamanouchi's R&D centre in [[Leiderdorp]] was established with the acquisition of the pharmaceutical division of [[Royal Gist Brocades]] in 1991. |
Both companies started their overseas expansion at about the same time, opening offices in [[Taiwan]] in 1962 and 1963, respectively, and in the [[United States]] and Europe from 1977 onwards. Fujisawa acquired '''Lyphomed''' in 1990 and thereafter established its US R&D centre in [[Deerfield, Illinois]]. Yamanouchi's R&D centre in [[Leiderdorp]] was established with the acquisition of the pharmaceutical division of [[Royal Gist Brocades]] in 1991. |
||
Revision as of 18:29, 15 September 2009
 | |
| Company type | Public KK (TYO: 4503) |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 2005 (from merger) |
| Headquarters |  Tokyo, Japan |
Key people | Masafumi Nogimori, President & CEO |
| Revenue |  ¥ 972,586 million JPY (FY 2007) |
| ¥ 177,437 million JPY (FY 2007) | |
Number of employees | 13,900 (2007) |
| Website | www.astellas.com |
Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha, TYO: 4503) is a Japanese pharmaceutical company, formed on 1 April, 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社, Fujisawa Yakuhin Kōgyō Kabushiki-gaisha).
Astellas' franchise areas are urology, immunology (transplantation), dermatology, cardiology, and infectious disease. Priority areas for R&D are infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system.
The company's headquarters are in Tokyo, with research centres in Tsukuba and Osaka. Clinical development is centred in Deerfield, Illinois and Leiderdorp, Netherlands. Combined revenues of the two pre-merger companies were $7.9 billion in 2004. Worldwide the company employs about 17,000 people.
History
Fujisawa Shoten was started in 1894 by Tomokichi Fujisawa in Osaka, and was renamed Fujisawa Pharmaceutical Co. in 1943.
Yamanouchi Yakuhin Shokai was started in 1923 by Kenji Yamanouchi in Osaka. The company was renamed Yamanouchi Pharmaceutical Co. in 1940 and moved to Tokyo in 1942.
Both companies started their overseas expansion at about the same time, opening offices in Taiwan in 1962 and 1963, respectively, and in the United States and Europe from 1977 onwards. Fujisawa acquired Lyphomed in 1990 and thereafter established its US R&D centre in Deerfield, Illinois. Yamanouchi's R&D centre in Leiderdorp was established with the acquisition of the pharmaceutical division of Royal Gist Brocades in 1991.
Fujisawa and Yamanouchi combined in a "merger of equals," forming Astellas Pharma on 1 April, 2005.
Products
Some of the key products produced by Astellas include:
- Prograf (tacrolimus) - Prevention of post-transplant organ rejection
- Protopic (tacrolimus ointment) - Atopic dermatitis (eczema)
- Amevive (alefacept) - Plaque psoriasis
- VESIcare (solifenacin succinate) - Overactive bladder (OAB)
- Flomax (tamsulosin hydrochloride) - Benign prostatic hyperplasia (BPH)
- Adenocard (adenosine injection) - Pharmacologic stress agent for myocardial perfusion scan
- Adenoscan (adenosine injection) - Pharmacologic stress agent for myocardial perfusion scan
- Lexiscan (regadenoson injection) - Pharmacologic stress agent for myocardial perfusion scan
- Vaprisol (conivaptan) - Hyponatremia
- AmBisome (amphotericin B) - Anti-fungal
- Mycamine (micafungin sodium) - Anti-fungal
- Vibativ (telavancin) - Antibiotic
References
External links
 | This article about a Japanese corporation- or company-related topic is a stub. You can help Wikipedia by expanding it. |
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |